Developer docs
API playgroundTry for free, no card

Search company profiles

LASCCO

Full company profile

uuid003ew9t

Namestring
LASCCO
Legal namestring
LASCCO SA
Websiteurl
lascco.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

LASCCO SA is a privately held Swiss diagnostics company headquartered in Epalinges, Switzerland, that developed Pancreatic Stone Protein (PSP), a novel sepsis biomarker measured from a drop of blood to provide early warning of sepsis risk in high-risk hospital patients. The PSP biomarker correlates with sepsis progression and remains accurate in confounding clinical settings such as burn injuries, post-trauma, and post-surgery, with more than 80 peer-reviewed publications supporting its clinical evidence base. LASCCO's commercial offering centers on a sepsis diagnostics suite comprising two productized formats: the IVD CAPSULE PSP, a point-of-care capsule commercialized by Abionic SA, and the PSP CLIA Solution, a chemiluminescent immunoassay format developed in collaboration with Fapon for the Chinese market.

The company operates an asset-light, licensing-only business model: it generates revenue exclusively through royalty arrangements with its commercial partners rather than through direct sales, distribution, or marketing. LASCCO has licensed global commercial rights to Abionic SA, which has secured FDA 510(k) clearance (October 2024), EU IVDR certification, EU CE mark, and Australian TGA certification for the IVD CAPSULE PSP. In October 2023, LASCCO and Abionic entered a strategic partnership with Fapon to bring the PSP biomarker onto Fapon's CLIA analyzer platform exclusively for China. End-customers are hospital healthcare providers — primarily intensive care units, emergency departments, and burn/trauma units — addressing the clinical problem of late sepsis recognition, which drives more than 11 million deaths annually and represents the single most expensive condition treated in hospitals globally.

Short descriptiontext

LASCCO SA is a Swiss diagnostics company that developed the Pancreatic Stone Protein (PSP) sepsis biomarker and generates revenue exclusively through licensing partnerships with Abionic SA (global point-of-care) and Fapon (China CLIA platform), serving hospital ICUs and emergency departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEpalinges, Switzerland
HQ citystring
Epalinges
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sepsis biomarker diagnostics, pancreatic stone protein, in-vitro diagnostics licensing, biomarker IP development, rapid sepsis detection
Industry2 codes
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-Vitro Diagnostics (Sepsis Biomarkers)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Royalties
TypeLicensing Royalties
Description

LASCCO generates revenue by licensing commercial rights for its PSP diagnostic test to strategic partners. The company licensed PSP commercial rights to Abionic SA and entered into a strategic partnership with Fapon for the Chinese market.

lascco.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LASCCO SA develops and owns the intellectual property for the Pancreatic Stone Protein (PSP), a biomarker used in a rapid diagnostic test for the early detection of sepsis. The company licenses the commercial rights to its PSP biomarker to Abionic SA for global commercialization and to Fapon for the Chinese market, earning royalties from these partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 50 million sepsis cases per year globally
+1 more record
Product overview1 text field

LASCCO has developed PSP (Pancreatic Stone Protein), a novel sepsis biomarker diagnostic test. The company's product portfolio consists of the core PSP biomarker technology and its commercialized derivatives: the IVD CAPSULE PSP (commercialized by Abionic SA, FDA-cleared) and the PSP CLIA solution (commercialized by Fapon for the Chinese market). These products form a sepsis diagnostics suite that provides rapid, lab-quality results from small blood samples to accelerate time-to-recognition of this life-threatening condition.

Product and service1 record
1Pancreatic Stone Protein (PSP) Sepsis Biomarker IP
CategoryIn-Vitro Diagnostics — Sepsis Biomarkers
Description

Proprietary Pancreatic Stone Protein (PSP) biomarker used in a rapid blood-based test for the early detection of sepsis. Licensed by LASCCO SA to IVD platform manufacturers such as Abionic SA (global) and Fapon (China), enabling them to offer a regulatory-cleared sepsis diagnostic to hospitals and clinical laboratories.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-10-26
Description

Abionic SA holds the commercial license rights for LASCCO's PSP diagnostic test. The IVD CAPSULE PSP test developed by Abionic has received FDA 510(k) clearance and is certified under EU IVDR and CE. This is a core licensing partnership where Abionic commercializes the PSP technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-26
Description

LASCCO and Abionic entered into a strategic partnership with Fapon in October 2023 to bring the PSP solution to China. Fapon is developing the PSP solution on its chemiluminescent immunoassay (CLIA) analyzer specifically for the Chinese market. This is a regional strategic collaboration for market expansion.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers4 records
TypeBroad incumbent
Description

Roche Diagnostics operates one of the largest IVD platforms globally, including Elecsys sepsis and infectious-disease panels on central lab analyzers. It is comparable as a broad incumbent whose installed immunoassay base overlaps with the hospital workflow that PSP targets.

TypeBroad incumbent
Description

bioMérieux is a global leader in microbiology and clinical diagnostics, with procalcitonin (VIDAS BRAHMS PCT) as the entrenched sepsis biomarker standard. It is a broad incumbent comparator because it defines the existing sepsis diagnostic workflow that PSP must displace or supplement across hospital ICUs worldwide.

TypeDirect peer
Description

Abionic is LASCCO's exclusive global commercialization partner for the IVD CAPSULE PSP and is itself a point-of-care diagnostics developer. It is directly comparable because it commercializes the same PSP biomarker on its proprietary capsule platform, making it simultaneously peer, partner, and primary revenue conduit for LASCCO.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LASCCO

In-Vitro Diagnostics (Sepsis Biomarkers)lascco.com

LASCCO SA is a Swiss diagnostics company that developed the Pancreatic Stone Protein (PSP) sepsis biomarker and generates revenue exclusively through licensing partnerships with Abionic SA (global point-of-care) and Fapon (China CLIA platform), serving hospital ICUs and emergency departments.

What LASCCO does

LASCCO SA is a privately held Swiss diagnostics company headquartered in Epalinges, Switzerland, that developed Pancreatic Stone Protein (PSP), a novel sepsis biomarker measured from a drop of blood to provide early warning of sepsis risk in high-risk hospital patients. The PSP biomarker correlates with sepsis progression and remains accurate in confounding clinical settings such as burn injuries, post-trauma, and post-surgery, with more than 80 peer-reviewed publications supporting its clinical evidence base. LASCCO's commercial offering centers on a sepsis diagnostics suite comprising two productized formats: the IVD CAPSULE PSP, a point-of-care capsule commercialized by Abionic SA, and the PSP CLIA Solution, a chemiluminescent immunoassay format developed in collaboration with Fapon for the Chinese market.

The company operates an asset-light, licensing-only business model: it generates revenue exclusively through royalty arrangements with its commercial partners rather than through direct sales, distribution, or marketing. LASCCO has licensed global commercial rights to Abionic SA, which has secured FDA 510(k) clearance (October 2024), EU IVDR certification, EU CE mark, and Australian TGA certification for the IVD CAPSULE PSP. In October 2023, LASCCO and Abionic entered a strategic partnership with Fapon to bring the PSP biomarker onto Fapon's CLIA analyzer platform exclusively for China. End-customers are hospital healthcare providers — primarily intensive care units, emergency departments, and burn/trauma units — addressing the clinical problem of late sepsis recognition, which drives more than 11 million deaths annually and represents the single most expensive condition treated in hospitals globally.

LASCCO firmographics

Firmographics
Name
LASCCO
Legal name
LASCCO SA
Website
https://lascco.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
LASCCO SA is a Swiss diagnostics company that developed the Pancreatic Stone Protein (PSP) sepsis biomarker and generates revenue exclusively through licensing partnerships with Abionic SA (global point-of-care) and Fapon (China CLIA platform), serving hospital ICUs and emergency departments.
Ownership category
akta.pro rank

LASCCO industry classification

Industry
Product category
In-Vitro Diagnostics (Sepsis Biomarkers)
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Sepsis biomarker diagnostics
  • Pancreatic stone protein
  • In-vitro diagnostics licensing
  • Biomarker IP development
  • Rapid sepsis detection

Where LASCCO is headquartered

Location

Headquarters

HQ city
Epalinges
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

LASCCO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing Royalties: LASCCO generates revenue by licensing commercial rights for its PSP diagnostic test to strategic partners. The company licensed PSP commercial rights to Abionic SA and entered into a strategic partnership with Fapon for the Chinese market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

LASCCO product offering

Product offering

Core offering

LASCCO SA develops and owns the intellectual property for the Pancreatic Stone Protein (PSP), a biomarker used in a rapid diagnostic test for the early detection of sepsis. The company licenses the commercial rights to its PSP biomarker to Abionic SA for global commercialization and to Fapon for the Chinese market, earning royalties from these partnerships.

Product overview

LASCCO has developed PSP (Pancreatic Stone Protein), a novel sepsis biomarker diagnostic test. The company's product portfolio consists of the core PSP biomarker technology and its commercialized derivatives: the IVD CAPSULE PSP (commercialized by Abionic SA, FDA-cleared) and the PSP CLIA solution (commercialized by Fapon for the Chinese market). These products form a sepsis diagnostics suite that provides rapid, lab-quality results from small blood samples to accelerate time-to-recognition of this life-threatening condition.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pancreatic Stone Protein (PSP) Sepsis Biomarker IP Proprietary Pancreatic Stone Protein (PSP) biomarker used in a rapid blood-based test for the early detection of sepsis. Licensed by LASCCO SA to IVD platform manufacturers such as Abionic SA (global) and Fapon (China), enabling them to offer a regulatory-cleared sepsis diagnostic to hospitals and clinical laboratories.

Quantifiable outcome

  • 50 million sepsis cases per year globally
  • +1 more outcomes

Companies that use LASCCO

Customer profile

Segments1 record

Ideal customer profiles1 record

LASCCO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

LASCCO partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Abionic SAcoreOEM/ Whitelabel/ Licensing Partner · 26 October 2023Abionic SA holds the commercial license rights for LASCCO's PSP diagnostic test. The IVD CAPSULE PSP test developed by Abionic has received FDA 510(k) clearance and is certified under EU IVDR and CE. This is a core licensing partnership where Abionic commercializes the PSP technology.
  • FaponcoreStrategic or Co-development Partner · 26 October 2023LASCCO and Abionic entered into a strategic partnership with Fapon in October 2023 to bring the PSP solution to China. Fapon is developing the PSP solution on its chemiluminescent immunoassay (CLIA) analyzer specifically for the Chinese market. This is a regional strategic collaboration for market expansion.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

LASCCO competitors and assessment

Company assessment

Peers

Broad incumbents

  • Roche Diagnostics: Roche Diagnostics operates one of the largest IVD platforms globally, including Elecsys sepsis and infectious-disease panels on central lab analyzers. It is comparable as a broad incumbent whose installed immunoassay base overlaps with the hospital workflow that PSP targets.
  • bioMérieux: bioMérieux is a global leader in microbiology and clinical diagnostics, with procalcitonin (VIDAS BRAHMS PCT) as the entrenched sepsis biomarker standard. It is a broad incumbent comparator because it defines the existing sepsis diagnostic workflow that PSP must displace or supplement across hospital ICUs worldwide.

Direct peers

  • Abionic SA: Abionic is LASCCO's exclusive global commercialization partner for the IVD CAPSULE PSP and is itself a point-of-care diagnostics developer. It is directly comparable because it commercializes the same PSP biomarker on its proprietary capsule platform, making it simultaneously peer, partner, and primary revenue conduit for LASCCO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

LASCCO social profiles

Digital presence

LASCCO compliance and trust

Trust signal

Compliance4 records

LASCCO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LASCCO leadership team

Management profile

Number of profiles

Profiles3 records

LASCCO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LASCCO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LASCCO

What does LASCCO do?

LASCCO SA develops and owns the intellectual property for the Pancreatic Stone Protein (PSP), a biomarker used in a rapid diagnostic test for the early detection of sepsis. The company licenses the commercial rights to its PSP biomarker to Abionic SA for global commercialization and to Fapon for the Chinese market, earning royalties from these partnerships.

Is LASCCO a public or private company?

LASCCO is a private company. It is classified as unknown and is currently operating.

When was LASCCO founded?

LASCCO was founded in 2007. It employs 1 to 10 people.

Where is LASCCO based?

LASCCO is headquartered in Epalinges, Switzerland, in the Europe region.

How does LASCCO make money?

One revenue line is on record: licensing Royalties.

Who are LASCCO's main competitors?

Siemens Healthineers is listed as a peer. Broad incumbents are Roche Diagnostics and bioMérieux. Abionic SA is listed as a direct peer.

Does LASCCO have an API?

No public API is recorded for LASCCO.

What industry is LASCCO in?

LASCCO's product category is In-Vitro Diagnostics (Sepsis Biomarkers). Its primary akta.pro industry code is HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales